These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10470171)

  • 1. CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin.
    Heinemann V; Schermuly MM; Stieber P; Schulz L; Jüngst D; Wilkowski R; Schalhorn A
    Anticancer Res; 1999; 19(4A):2433-5. PubMed ID: 10470171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.
    Ziske C; Schlie C; Gorschlüter M; Glasmacher A; Mey U; Strehl J; Sauerbruch T; Schmidt-Wolf IG
    Br J Cancer; 2003 Oct; 89(8):1413-7. PubMed ID: 14562009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
    Stemmler J; Stieber P; Szymala AM; Schalhorn A; Schermuly MM; Wilkowski R; Helmberger T; Lamerz R; Stoffregen C; Niebler K; Garbrecht M; Heinemann V
    Onkologie; 2003 Oct; 26(5):462-7. PubMed ID: 14605463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
    Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
    Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
    J Clin Oncol; 2006 Jan; 24(3):379-85. PubMed ID: 16344320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
    Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
    Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features of long time survivors with unresectable pancreatic cancer treated by gemcitabine alone].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Fujisawa N; Yoneda M; Abe Y; Inamori M; Kawamura H; Kirikoshi H; Shimamura T; Kubota K; Sakaguchi T; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):207-12. PubMed ID: 16484857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer.
    Brodowicz T; Wolfram RM; Köstler WJ; Tomek S; Vaclavik I; Steger GG; Teleky B; Függer R; Jakesz R; Zielinski CC
    Anticancer Drugs; 2000 Sep; 11(8):623-8. PubMed ID: 11081453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
    Wong D; Ko AH; Hwang J; Venook AP; Bergsland EK; Tempero MA
    Pancreas; 2008 Oct; 37(3):269-74. PubMed ID: 18815548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
    Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
    Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
    Saif MW; Syrigos K; Penney R; Kaley K
    Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
    Ko AH; Hwang J; Venook AP; Abbruzzese JL; Bergsland EK; Tempero MA
    Br J Cancer; 2005 Jul; 93(2):195-9. PubMed ID: 15999098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
    Rocha Lima CM; Savarese D; Bruckner H; Dudek A; Eckardt J; Hainsworth J; Yunus F; Lester E; Miller W; Saville W; Elfring GL; Locker PK; Compton LD; Miller LL; Green MR
    J Clin Oncol; 2002 Mar; 20(5):1182-91. PubMed ID: 11870159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
    Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
    Hammad N; Heilbrun LK; Philip PA; Shields AF; Zalupski MM; Venkatramanamoorthy R; El-Rayes BF
    Asia Pac J Clin Oncol; 2010 Jun; 6(2):98-105. PubMed ID: 20565421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
    Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E
    Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
    Halm U; Schumann T; Schiefke I; Witzigmann H; Mössner J; Keim V
    Br J Cancer; 2000 Mar; 82(5):1013-6. PubMed ID: 10737382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
    Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.